169 related articles for article (PubMed ID: 25043969)
1. Short-term efficacy of intravitreal triamcinolone acetonide for bevacizumab-resistant diabetic macular oedema.
Kim JH; Lee TG; Lew YJ
Acta Ophthalmol; 2015 Mar; 93(2):e178-9. PubMed ID: 25043969
[No Abstract] [Full Text] [Related]
2. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
Sheth S; Rush R; Natarajan S; Gillies M
Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a single intravitreal injection of bevacizumab versus triamcinolone acetonide as primary treatment for diffuse diabetic macular oedema.
Penha FM; Maia M; Cardillo JA; Arevalo JF; Wu L; Rodriguez FJ; Berrocal MH; Farah ME;
Acta Ophthalmol; 2012 Mar; 90(2):e160-1. PubMed ID: 21470386
[No Abstract] [Full Text] [Related]
4. Combined therapy with intravitreal bevacizumab and posterior subtenon triamcinolone acetonide injection in diabetic macular oedema.
Kim HD; Kang KD; Choi KS; Rhee MR; Lee SJ
Acta Ophthalmol; 2014 Nov; 92(7):e589-90. PubMed ID: 24866832
[No Abstract] [Full Text] [Related]
5. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
Rensch F; Spandau UH; Wickenhäuser A; Jonas JB
Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
[No Abstract] [Full Text] [Related]
6. Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab.
Jeon S; Lee WK
Retina; 2014 Aug; 34(8):1606-11. PubMed ID: 24553409
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).
Paccola L; Costa RA; Folgosa MS; Barbosa JC; Scott IU; Jorge R
Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109
[TBL] [Abstract][Full Text] [Related]
8. Diabetic macular oedema in 2011: what are the options for refractory cystic oedema?
Wickremasinghe S
Clin Exp Ophthalmol; 2011; 39(7):595-7. PubMed ID: 22452678
[No Abstract] [Full Text] [Related]
9. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.
Soheilian M; Garfami KH; Ramezani A; Yaseri M; Peyman GA
Retina; 2012 Feb; 32(2):314-21. PubMed ID: 22234244
[TBL] [Abstract][Full Text] [Related]
10. Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema.
Sonoda S; Sakamoto T; Yamashita T; Otsuka H; Shirasawa M; Kakiuchi N; Uchino E; Terasaki H; Kawano H
Invest Ophthalmol Vis Sci; 2014 Jun; 55(6):3979-85. PubMed ID: 24906857
[TBL] [Abstract][Full Text] [Related]
11. Comparison of grid laser, intravitreal triamcinolone, and intravitreal bevacizumab in the treatment of diffuse diabetic macular edema.
Sobaci G; Ozge G; Erdurman C; Durukan HA; Bayraktar ZM
Ophthalmologica; 2012; 227(2):95-9. PubMed ID: 21893972
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
13. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
Kumar V; Ghosh B; Raina UK; Goel N
Am J Ophthalmol; 2008 Dec; 146(6):974; author reply 974-5. PubMed ID: 19027427
[No Abstract] [Full Text] [Related]
14. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
Cheng KC; Wu WC; Chen KJ
Eye (Lond); 2009 Nov; 23(11):2023-33. PubMed ID: 19798117
[TBL] [Abstract][Full Text] [Related]
16. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy in diabetic macular oedema and retinal vein occlusion--past and present.
Koss MJ; Naser H; Sener A; Ackermann H; Al-Sarireh F; Singh P; Koch FH
Acta Ophthalmol; 2012 Sep; 90(6):580-9. PubMed ID: 20636486
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results.
Kriechbaum K; Prager S; Mylonas G; Scholda C; Rainer G; Funk M; Kundi M; Schmidt-Erfurth U;
Eye (Lond); 2014 Jan; 28(1):9-15; quiz 16. PubMed ID: 24336297
[TBL] [Abstract][Full Text] [Related]
20. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.
Akinci A; Muftuoglu O; Altınsoy A; Ozkılıc E
Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
